Navigation Links
Brookdale to Present at Citi Small & Mid-Cap Conference on March 17
Date:3/11/2008

CHICAGO, March 11 /PRNewswire-FirstCall/ -- Brookdale Senior Living Inc. (NYSE: BKD) today announced that management will make a presentation regarding the Company at the Citi Small & Mid-Cap Conference on Monday, March 17, 2008 at 3:40 p.m. PT at the Four Seasons at Mandalay Bay in Las Vegas, Nevada.

The presentation is being webcast live and can be accessed through the Citi Conference website at http://www.veracast.com/webcasts/citigroup/smallmidcap08/72104196.cfm as well as through the Investor Relation's section of the company's website at http://www.brookdaleliving.com. A replay of the webcast will be available through the Citigroup Conference website until April 18, 2008. The presentation slides will also be available during and after the presentation through the Investor Relations section of the Brookdale Senior Living website.

About Brookdale Senior Living

Brookdale Senior Living Inc. is a leading owner and operator of senior living facilities throughout the United States. The Company is committed to providing an exceptional living experience through properties that are designed, purpose-built and operated to provide the highest-quality service, care and living accommodations for residents. Currently the Company owns and operates independent living, assisted living, and dementia-care facilities and continuing care retirement centers, with 550 facilities in 35 states and the ability to serve over 52,000 residents.


'/>"/>
SOURCE Brookdale Senior Living Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Brookdale Announces Third Quarter Common Stock Dividend of $0.50
2. Brookdale Announces Third Quarter 2007 Release and Earnings Call
3. Brookdale Announces Third Quarter 2007 Results
4. Brookdale Senior Living Announces Enhanced Web Site
5. Brookdale Announces Fourth Quarter Common Stock Dividend of $0.50
6. Brookdale Senior Living Announces Changes in Senior Management and Board of Directors
7. Brookdale Announces Fourth Quarter and Full Year 2007 Release and Earnings Call
8. Brookdale Announces Fourth Quarter and Full Year 2007 Results
9. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
10. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
11. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Edvance360, a leading provider of eLearning solutions, ... as well as 2011 winner and six-time-finalist for the ... announced that Brooke Education Services, Northwest Academy, Typewell, Dialysis ... Bureau of Canada (IAB Canada), StarSVCS, and HMG Plus, ... to welcome each new client to the growing Edvance360 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... a U.S. Food and Drug Administration (FDA)-approved treatment ... is as effective at reducing fracture risk as ... suppressing bone loss. With the use of wide- ... researchers carried out experiments at the U.S. Department ... Argonne National Laboratory that revealed an additional mechanism ...
(Date:8/29/2014)... the Washington University School of Medicine have identified one ... providing important insight that could lead to new therapies, ... Cell Host & Microbe . , In work ... Photon Source, the researchers developed a detailed map of ... host protein that takes signaling molecules in and out ...
(Date:8/29/2014)... August 30, 2014 Top10inaction, a professional ... conference providers in the online service industry for the ... global leaders Webex, GotoMeeting and Infinite. , With over ... have to determine which provider is ideally a good ... businesses search for compelling consumer goods and services agencies ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... Blue Plan Experienced a 15 Percent Increase ... a New Report from HealthLeaders-InterStudy, NASHVILLE, ... of managed care market intelligence, reports that ... medication use,through pharmacy programs and public education ...
... Health,Care Systems, Inc. (HCS), a leading provider ... medication reconciliation solutions, has entered,into an agreement with ... not-for-profit hospitals in the nation with 881 licensed,acute ... facility for The,University of Alabama at Birmingham,s Family ...
... treatment could help 3.3 million U.S. sufferers, ... Medical, Inc. today,announced that 98.4 percent of ... called Barrett,s esophagus were free of the ... the HALO ablation,system. The results were published ...
... release of milk in humans, animals , , FRIDAY, July 18 ... speaking? , Researchers have discovered that babies nursing at ... to release of oxytocin, known as the "trust" hormone in ... to be involved in trust and love in both humans ...
... restored brain,s ability to make new cells , , FRIDAY, July ... day may lead to health issues, including depression, a new ... a causal link between abstinence from alcohol drinking and depression," ... and pharmacology in the University of North Carolina School of ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
Cached Medicine News:Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 3Health News:Suckling Infant Triggers 'Trust' Hormone in Moms 2Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
Medicine Products: